Current Assets (USD, millions)

Cash and Cash Equivalents (USD, millions)

Accounts Receivable (USD, millions)

Inventory (USD, millions)

Non-Current Assets (USD, millions)

Property, Plant, and Equipment (PP&E) (USD, millions)

Goodwill (USD, millions)

Intangible Assets (USD, millions)

Current Liabilities (USD, millions)

Accounts Payable (USD, millions)

Short-term Debt (USD, millions)

Accrued Expenses (USD, millions)

Non-Current Liabilities (USD, millions)

Long-term Debt (USD, millions)

Lease Liabilities (USD, millions)

Deferred Tax Liabilities (USD, millions)

Shareholders' Equity (USD, millions)

Retained Earnings (USD, millions)

Common Stock (USD, millions)

Additional Paid-in Capital (USD, millions)

6e8cc0efce86cd5035fdb883e2fc2dd7e18fd9efc04547ae57ae4920013150af

Percentage change in combined global sales for Cozaar and Hyzaar (percent)

Percentage change in worldwide sales of Singulair (percent)

Percentage change in global sales of Nasonex (percent)

Percentage change in global sales of Dulera (percent)

Percentage change in sales of Arcoxia (percent)

Percentage change in sales of Diprospan (percent)

Percentage change in worldwide sales of Proscar (percent)

Percentage change in worldwide sales of Nexplanon (percent)

Percentage change in worldwide sales of NuvaRing (percent)

Percentage change in worldwide sales of Marvelon and Mercilon (percent)

Percentage change in worldwide sales of Follistim AQ (percent)

Percentage change in worldwide sales of ganirelix acetate injection (percent)

Percentage change in worldwide sales of Jada (percent)

Percentage change in sales of Renflexis (percent)

Percentage change in sales of Ontruzant (percent)

Percentage change in sales of Brenzys (percent)

Percentage change in combined global sales of Zetia and Vytorin (percent)

Percentage change in sales of Atozet (percent)

f1628683aa00982fad3fb6c35c24b70ced35be22443fab4e5f15668906563342

Net income [USD, millions]

Depreciation [USD, millions]

Amortization [USD, millions]

Acquired in-process research and development and milestones [USD, millions]

Deferred income tax (benefit) expense [USD, millions]

Stock-based compensation [USD, millions]

Unrealized foreign exchange (gain) loss [USD, millions]

Other Adjustments to reconcile net income [USD, millions]

Accounts receivable, net changes [USD, millions]

Inventories, net changes [USD, millions]

Other current assets, net changes [USD, millions]

Trade accounts payable, net changes [USD, millions]

Accrued and other current liabilities, net changes [USD, millions]

Income taxes payable, net changes [USD, millions]

Other, net changes in assets and liabilities [USD, millions]

Net Cash Flows Provided by Operating Activities [USD, millions]

Capital expenditures [USD, millions]

Purchase of product rights and asset acquisition, net of cash acquired [USD, millions]

Net Cash Flows Used in Investing Activities [USD, millions]

Proceeds from debt [USD, millions]

Repayments of debt [USD, millions]

Employee withholding taxes related to stock-based awards [USD, millions]

Dividend payments [USD, millions]

Net Cash Flows Used in Financing Activities [USD, millions]

Effect of Exchange Rate Changes on Cash and Cash Equivalents [USD, millions]

Net Increase (Decrease) in Cash and Cash Equivalents [USD, millions]

Cash and Cash Equivalents, Beginning of Period [USD, millions]

Cash and Cash Equivalents, End of Period [USD, millions]

2aff07e616b04b709a12a1404d093cab785a2422d419f42f306a5f4856fd1e06

5040c1bb07f8ec1c10ee37091bf6f0fcc3b6cc85db0738f02f2368643b8782d9

United States

Europe and Canada

Asia Pacific and Japan

China

Latin America, Middle East, Russia, and Africa

Other

Total Revenue

9b7199f1280cb0f62aeb04cbed7e0eda2fd1413b0fb00729288f5947eb38ec99

Adjustments for Non-Cash Items (USD, millions)

Stock-Based Compensation (USD, millions)

Changes in Working Capital (USD, millions)

Capital Expenditures (USD, millions)

Proceeds from Debt (USD, millions)

Repayments of Debt (USD, millions)

Share Repurchases (USD, millions)

Dividend Payments (USD, millions)

Net Change in Cash (USD, millions)

4d5b26ec5e091916f43832c6500b197b17c147cf53dddafd8170c5469e2798fd

Total Revenue (USD, millions)

Cost of Goods Sold (COGS) (USD, millions)

SG&A (USD, millions)

R&D (USD, millions)

D&A (USD, millions)

Interest Expense (USD, millions)

Operating Income (EBIT) (USD, millions)

Net Income (USD, millions)

EPS - Basic (USD/share)

EPS - Diluted (USD/share)

acce3cfaf29977f60262735ecd578ea9833019e95e283f78f1d115a25bc22423

Revenues (USD, millions)

Cost of sales (USD, millions)

Gross profit (USD, millions)

Selling, general and administrative (USD, millions)

Research and development (USD, millions)

Acquired in-process research and development and milestones (USD, millions)

Restructuring costs (USD, millions)

Interest expense (USD, millions)

Exchange losses (USD, millions)

Other expense, net (USD, millions)

Income before income taxes (USD, millions)

Income tax (benefit) expense / Taxes on income (USD, millions)

Net income (USD, millions)

5781960b6cb73befbfd083c6c5842708b7c317b305cc0d3ff2213aeb641fb00d

Cash and cash equivalents (USD, millions)

Long-term debt (USD, millions)

48391648f380e23eab7ecd977d7706ee24e3e25af2b5b51e0f41c6929c2021a0

Organon & Co (OGN)

Financials